临床上使用的与ICD有关的化疗药物数量有限，如阿霉素、米托蒽醌、奥沙利铂和环磷酰胺等[17]。然而这些药物都不在现代NSCLC化疗方案之中。在晚期NSCLC的一线研究中，ICI联合顺铂或卡铂双药化疗（以培美曲塞[18]或紫杉醇[19，20]作为第二种药物）对无进展生存率（PFS）和OS预后都有显著改善。Hato等人描述了铂类化...
Yang G, Liu R, Li P, Yang Y, Wang Y, Mao H, Tang X. Clinical and structural insights into the rare but oncogenic HER2-activating missense mutations in non-small cell lung cancer: a retrospective ATLAS cohort study. Discov Oncol. 2024 Jul 16;15(1):285. doi: 10.1007/s12672-024-01154...
Yang G, Liu R, Li P, Yang Y, Wang Y, Mao H, Tang X. Clinical and structural insights into the rare but oncogenic HER2-activating missense mutations in non-small cell lung cancer: a retrospective ATLAS cohort study. Discov Oncol. 2024 Jul 16;15(1):285. doi: 10.1007/s12672-024-01154...
NSCLC diagnosis was determined through ICD9/10 codes. NGS tests ordered were limited to xT/xR (solid tumor DNA and RNA), xE (solid tumor whole exome), or xF (circulating tumor DNA). Aggregate unique patients with orders were summated on a per site basis. Descriptive statistics were used ...
放疗(RT)可以诱导肿瘤特异性免疫反应,尤其是免疫原性细胞死亡(ICD),表达和/或释放多种危险相关分子模式DAMPs(如ATP、细胞核酸、HMGB1、ANXA1)、细胞因子(如INF-1、CCL2、CXCL1和CXCL10)及ER分子伴侣(如钙网蛋白、ERp57、Hsp70和Hsp90)。这些ICD相关的分子被天然免疫细胞识别并促进这些细胞的激活和成熟,之后天然...
The interaction between cancer cells and the tumor microenvironment (TME) is a crucial factor in determining the development of human neoplasms. Organellar and cellular stress are induced during immunogenic cell death (ICD), a particularly functional response pattern. ICD is a separate but poorly ...
某些类别化疗药物可诱导免疫原性细胞死亡(ICD),促进抗原递呈,增强抗肿瘤免疫反应。铂衍生物是NSCLC CCRT治疗基石,上调APC上Ⅰ类MHC 表达,还可去除MDSCs和Tregs,增加TME内T细胞和树突状细胞。化疗有骨髓抑制和免疫抑制作用,如上调肿瘤细胞PD-L1,化疗对免疫系统的...
WANG X, et al. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blin...
在非小细胞肺癌(NSCLC)中,与人表皮生长因子受体 2(HER2)扩增或外显子 20 插入不同,HER2 胞外结构域(ECD)、跨膜结构域(TMD)和细胞内结构域(ICD)错义突变被认为具有致癌性。然而,在 NSCLC 中,其分子亚…
Purpose: Administrative claims data using the ICD-9-CM or ICD-10-CM coding systems are not detailed enough to distinguish between lung cancer subtypes, which presents challenges for real-world research. This study updated and validated a previous treatment-based algorithm that uses claims data to ...